LEHI, Utah and LOUISVILLE, Ky., May 29, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced it has been named a 2025–2026 Best Company to Work For by U.S. News & World Report. In addition to this national honor, U.S. News & World Report also named Waystar a Best Company to Work For in both the Health Care and Research sector and the West region.
U.S. News & World Report evaluated the 5,000 largest public companies based on employee sentiment across six key factors: pay and benefits; work-life balance and flexibility; job and company stability; physical and psychological comfort; sense of belongingness and esteem; and career opportunities and professional development. Waystar earned a place in the top 6% of companies overall, as well as within the top 25% of its industry and region.
"We're honored to be recognized by U.S. News & World Report alongside so many respected companies," said Matt Hawkins, Chief Executive Officer of Waystar. "This recognition reflects the culture we've built — one rooted in innovation, shared values, and a deep commitment to our mission to simplify healthcare payments. I'm grateful to our dedicated team members, whose passion and purpose power the mission-critical software we deliver to more than one million providers nationwide."
The recognition adds to a growing list of accolades Waystar has received for workplace culture and team member satisfaction, including designations from Fortune's Great Place to Work®, Becker's Healthcare, and the Women Tech Council's Shatter List.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

| Last Trade: | US$36.18 |
| Daily Change: | -0.86 -2.32 |
| Daily Volume: | 481,225 |
| Market Cap: | US$6.920B |
October 29, 2025 October 01, 2025 September 10, 2025 September 09, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load